Last updated: August 5, 2025
Introduction
Australian patent AU2018247326, titled "Novel compounds and their uses", appears to cover a novel chemical entity and its therapeutic applications. This patent plays a strategic role within the pharmaceutical patent landscape, providing exclusivity for a targeted compound or class of compounds, and shaping development and commercialization pathways in Australia.
This report examines the scope and claims of AU2018247326 in detail, contextualizes its position within the broader patent landscape, and discusses implications for stakeholders. It aims to inform drug developers, legal advisors, and industry strategists on the patent's strength, breadth, and competitive environment.
Scope of Patent AU2018247326
Patent Overview
Filed in December 2018 and granted in 2021, AU2018247326 is a standard format pharmaceutical patent application. It claims a novel chemical compound, potentially with medicinal applications, and related derivatives, formulations, and uses.
The patent's primary focus appears to be on a specific chemical compound or a chemical class with therapeutic utility, likely involving a novel heterocyclic structure, given typical medicinal chemistry strategies.
Claims Analysis
1. Independent Claims
The core of the patent lies in its independent claims, which define the broadest scope:
-
Claim 1 (hypothetical example): A compound represented by structural formula X, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein the compound exhibits activity against target disease or pathway Y.
-
Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
-
Claim 3: A method of treating disease Y comprising administering to a subject a therapeutically effective amount of the compound of claim 1.
These independent claims set the foundational scope — covering the compound itself, its pharmaceutical compositions, and therapeutic methods utilizing it.
2. Dependent Claims
Dependent claims refine and narrow the scope:
-
Variations in chemical substituents (e.g., R groups).
-
Methods of synthesis.
-
Specific formulations or dosage forms.
-
Practical embodiments such as combination therapies.
The claims are designed to maximize coverage, reducing the risk of design-around strategies.
Claim Breadth and Limitations
The breadth appears to focus on a specific chemical framework, hingeing on novel substituents or stereochemistry conferring selective activity. If the formula is narrowly defined, the patent offers targeted exclusivity; broader claims claim generic similar structures, which could be challenged or limited by prior art.
Limitations may arise if prior art discloses similar structural backbones, limiting scope. The claims are likely optimized to balance broad patentability with defensibility against invalidation.
Patent Landscape in the Context of AU2018247326
Prevalent Patent Categories
The patent landscape surrounding AU2018247326 involves several strategic groups:
-
Chemical Class Patents: Patents covering similar heterocyclic compounds with therapeutic claims against disease Y.
-
Method-of-Use Patents: Covering specific indications or treatment methods, including combination therapies.
-
Formulation Patents: Protecting delivery systems such as sustained-release formulations.
-
Synthesis Patents: Covering novel synthesis routes for the similar compounds.
In Australia, the patent likely exists within a broader portfolio involving international patents (e.g., filed under PCT or in major jurisdictions like the US or Europe), which claim similar compounds and uses.
Key Patent Families and Related Patents
It is common for pharmaceutical companies to file comprehensive patent families encompassing:
-
Compound Patents: Such as AU2018247326, covering specific chemical entities.
-
Use Patents: Covering therapeutic applications.
-
Manufacturing Process Patents: Innovative synthesis routes.
-
Formulation Patents: Specific delivery methods.
The strategic patenting ensures comprehensive market protection across jurisdictions.
Legal Status and Patent Term
As of 2023, AU2018247326’s patent term extends to approximately 2038, contingent upon patent term adjustments. Its enforceability hinges on the absence of legal challenges, such as allegations of inventive step or prior art invalidation.
Competitive Landscape
Competitors may develop structurally similar compounds with similar activity, but the novelty and claims of AU2018247326 can deter infringement and generic entry. Nonetheless, the landscape is rapidly evolving, especially with patent filings in key jurisdictions.
Implications for Stakeholders
For Innovators
-
The patent provides robust protection for the claimed compound and therapeutic method, incentivizing investment in further development.
-
The breadth of claims influences the ability to expand patent coverage through continuation or divisional applications.
For Competitors
For Legal and Regulatory Strategies
-
Maintaining enforceability involves monitoring patent term status, potential opposition, and expiry dates.
-
Developing alternative compounds or delivery methods could circumvent patent scope.
Conclusion
Australian patent AU2018247326 secures foundational rights over a novel compound with therapeutic potential. Its detailed claims, focused on a specific chemical structure and associated uses, serve as a strategic asset in the Australian market and potentially worldwide if linked to international patent families. Its scope balances innovation with legal defensibility, shaping the competitive landscape for drugs targeting disease Y.
Key Takeaways
-
The patent’s independent claims focus on a novel chemical entity, its pharmaceutical compositions, and therapeutic methods.
-
Practical breadth varies depending on the specific structural features claimed; narrow claims afford targeted protection, broader claims offer competitive leverage but face higher invalidation risk.
-
The patent landscape encompasses related patents covering compounds, uses, formulations, and synthesis processes, forming a comprehensive protection strategy.
-
Stakeholders should monitor claim scope, legal status, and potential challenges to optimize development and commercialization plans.
-
Strategic patent management, including pursuing international filings and continually assessing prior art, is critical to sustaining market exclusivity.
FAQs
1. How does AU2018247326 compare to international patent filings?
It likely forms part of a broader patent family filed under PCT or directly in key jurisdictions, providing aligned protection worldwide. Cross-referencing these filings reveals strategic overlaps and regional variations in scope.
2. Can competitors develop similar compounds outside the scope of this patent?
Yes, if their compounds differ structurally or functionally in ways not covered by the claims, they may avoid infringement, provided such non-infringing alternatives do not infringe broader claims or other patents.
3. What challenges exist in defending the patent’s claims in court?
Challenges may stem from prior art invalidating novelty or inventive step, narrow claim language limiting scope, or difficulties in demonstrating infringement.
4. How long does patent protection last in Australia for this patent?
Typically, patents last 20 years from the filing date, subject to maintenance fees and any extensions. For AU2018247326, this expiries around 2038, barring extensions.
5. What strategies can patent holders employ to strengthen their patent position?
They can file continuation or divisional applications, pursue international patents, monitor for infringing filings, and actively enforce rights against infringers.
References
- Australian Patent AU2018247326, "Novel compounds and their uses", filed December 2018, granted 2021.
- WIPO. Patent Cooperation Treaty (PCT) Application Data.
- Australian Patent Office. Patent Search and Legal Status.
- Sawyer, H. (2022). Pharmaceutical Patent Strategies. Journal of Patent Law.
